# Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children

> **NCT02153112** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 840 (actual)

## Conditions studied

- Norovirus

## Interventions

- **BIOLOGICAL:** GI.1/GII.4 (15/15)
- **BIOLOGICAL:** GI.1/GII.4 (15/50)
- **BIOLOGICAL:** GI.1/GII.4 (50/50)
- **BIOLOGICAL:** GI.1/GII.4 (50/150)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02153112
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-23
- **Primary completion:** 2018-06-20
- **Final completion:** 2018-06-20
- **Target enrollment:** 840 (ACTUAL)
- **Last updated:** 2019-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02153112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02153112, "Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02153112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*